V. Bryan Lawlis - Jun 7, 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Director
Signature
/s/ James Kastenmayer, by power of attorney
Stock symbol
AGLE
Transactions as of
Jun 7, 2022
Transactions value $
$0
Form type
4
Date filed
6/9/2022, 09:15 PM
Previous filing
May 26, 2022
Next filing
Apr 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Director Stock Option (right to buy) Award $0 +43K $0.00 43K Jun 7, 2022 Common Stock 43K $0.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney